GP IIb/IIIa inhibitors during primary percutaneous coronary intervention for STEMI: new trial and registry data.
Primary percutaneous coronary intervention (PCI) with adjunctive glycoprotein (GP) IIb/IIIa receptor inhibitor therapy administered in the cardiac catheterization laboratory is the optimal reperfusion strategy for patients with ST-elevation myocardial infarction. Most available data regarding these agents are from trials comparing abciximab to placebo alone. Noninferiority trials comparing small-molecule GP IIb/IIIa receptor inhibitors, such as tirofiban and eptifibatide with abciximab, have used markers for myocardial reperfusion as primary end points but are underpowered to detect significant differences in hard clinical outcomes. Such a trial would need to enroll a very large number of patients and thus make it practically impossible to perform. Registry data reveal that most patients undergoing primary PCI are treated with small-molecule GP IIb/IIIa receptor inhibitors in clinical practice, and no observed difference is observed in safety and efficacy when compared with patients treated with abciximab therapy.
Tamhane
Umesh U
UU
Department of Medicine, Division of Cardiovascular Medicine, University of Michigan and VA Ann Arbor Health Care System, University of Michigan Cardiovascular Center, Ann Arbor, MI 48109-5853, USA.
Gurm
Hitinder S
HS
D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000494:pharmacology* / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D016896:Treatment Outcome
D019039:Platelet Glycoprotein GPIIb-IIIa Complex